

**Supplementary Information:**

**Albumin as a “Trojan Horse” for Polymeric Nanoconjugates Transendothelial Transport  
across Tumor Vasculatures for Improved Cancer Targeting**

Qian Yin,<sup>†</sup> Li Tang,<sup>†</sup> Kaimin Cai,<sup>†</sup> Xujuan Yang,<sup>‡</sup> Lichen Yin,<sup>†</sup> Yanfeng Zhang,<sup>†</sup> Lawrence W. Dobrucki,<sup>§</sup> William G. Helderich,<sup>‡</sup> Timothy M. Fan,<sup>††</sup> Jianjun Cheng<sup>†,\*</sup>

<sup>†</sup>Department of Material Sciences and Engineering, <sup>‡</sup>Department of Food Science and Human Nutrition, <sup>§</sup>Department of Bioengineering, <sup>††</sup>Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

\* Address correspondence to [jianjunc@illinois.edu](mailto:jianjunc@illinois.edu)

## Supplementary Figure Legends

**Fig. S1.** DLS analysis of Doxo-PheLA NCs in water (0.5 mg/mL).

**Fig. S2.** The  $^{64}\text{Cu}$  labeling stability of  $^{64}\text{Cu}$ -Alb-NCs and  $^{64}\text{Cu}$ -PEG-NCs in human serum buffer (human serum:PBS=1:1, v/v).

**Fig. S3.** *In vivo* tumor accumulation (A) and biodistribution (B) of  $^{64}\text{Cu}$ -Alb-NCs and  $^{64}\text{Cu}$ -PEG-NCs in MCF-7 breast cancer xenograft model assessed by  $\gamma$ -counter. All the data was presented as percentage of injected dose per gram of tissues (% I.D.  $\text{g}^{-1}$ ).

**Fig. S4.** Representative images of the tumor from each treatment group.

**Fig. S5.** % Body weight over the *in vivo* tumor reduction study. No significant body weight drop (>20%) was observed.

**Table S1.** Radius of Alb-NCs as a function of albumin concentration determined by FCS measurements.

## Supplementary Figures

**Fig. S1**




Fig. S2





Fig. S3



**Fig. S4**





Fig. S5



**Table S1**

Concentration of albumin ( $\mu\text{M}$ )	Particle radius (nm)	error
0	40	5
1	54	7
10	57	10
50	79.4	15
100	96.5	18
500	150	25
1000	156	30